Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 233

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 233
---
 of a new field-based team to support ZILRETTA after realigning our existing sales force to focus on EXPAREL. This transition impacted sales in 2025 as ZILRETTA is a promotionally sensitive product.

Net product sales of iovera° increased 14% and 5% in the three and nine months ended September 30, 2025 versus 2024, respectively, driven by increases in Smart Tip volume of 16% and 7%, partially offset by decreases in Smart Tip net selling price of 1% and 2%.

Bupivacaine liposome injectable suspension revenue increased 64% in the three months ended and decreased 21% in the nine months ended September 30, 2025 versus 2024, respectively, due to timing of orders placed by our commercial partner for veterinary use. Its related royalties increased 73% in the three months ended and decreased 6% in the nine months ended September 30, 2025 versus 2024, respectively, primarily due to both the timing of orders and the sales mix of vial sizes.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  45

The following tables provide a summary of activity with respect to our sales-related allowances and accruals related to EXPAREL and ZILRETTA for the nine months ended September 30, 2025 and 2024 (in thousands):

September 30, 2025Returns AllowancesPrompt Payment DiscountsService FeesVolume Rebates and ChargebacksGovernment RebatesTotalBalance at December 31, 2024$1,600 $1,308 $4,875 $4,863 $1,707 $14,353 Provision1,051 10,469 17,835 117,974 2,641 149,970 Payments(571)(10,296)(17,756)(117,511)(2,674)(148,808)Balance at September 30, 2025$2,080 $1,481 $4,954 $5,326 $1,674 $15,515 

September 30, 2024Returns AllowancesPrompt Payment DiscountsService FeesVolume Rebates and ChargebacksGovernmentRebatesTotalBalance at December 31, 2023$1,868 $1,308 $3,697 $